Fusion of ABL1 to BCR/TEL/NUP214 is observed in a large number of leukemia patients and allosteric stimulation of the normal ABL1 kinase activity enhanced the antileukemia effect of ABL1 tyrosine kinase inhibitors [24]. The gene discussed is BCR; the disease is leukemia.